# US 2024/0254228 A1 · Binding molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254228 A1
- Document ID: US20240254228A1
- Status: Published application
- Kind: A1
- Application number: 18/405,977
- Filed: 2024-01-05
- Published: 2024-08-01
- Earliest claimed: 2023-01-06
- Assignees: Immunocore Limited
- Applicants: Immunocore Limited
- Inventors: Nicole MAI; Arnaud TECHINE; Jakub JAWORSKI; Kate ATKIN; Nathaniel LIDDY; Vijaykumar KARUPPIAH; Ana PEREIRA RIBEIRO; Ana PENAS; Andrew CREESE; Emma GRANT; Stephen HARPER; Chandramouli CHILLAKURI; Eduardo MATEOS-DIAZ; Tamara ALEKSIC; Pedro CUADRADO RODENAS
- Web page: https://patentgrep.com/patent/US20240254228A1

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/30: from tumour cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/31: multispecific
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/524: CH2 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A binding molecule comprising a TCR alpha chain variable domain and a TCR beta chain variable domain variable domain, wherein the binding molecule has the property of binding to SLSNRLYYL (SEQ ID NO: 1) in complex with HLA-A*02, wherein each of the alpha chain variable domain and the beta chain variable domain comprises FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, where FR is a framework region and CDR is a complementarity determining region, the following combination of alpha chain CDRs and beta chain CDRs:
Alpha
Beta
CDR1
CDR2
CDR3
CDR1
CDR2
CDR3
NIATN
GYKTK
LAWGG
SGHAT
FQNNG
ASSLDWV
DY
TDKLI
V
GSGETQY
YIAAN
GYKTN
LAWGG
SGHGT
FHEEG
ASSVDWV
DF
TDLLP
V
GDGERQY

### Claim at position 3

10-13. (canceled)

### Claim 14 (depends on 9)

The binding molecule of claim 9, wherein the alpha chain variable domain framework regions comprise the following sequences:
FR1—LAKTTQPISMDSYEGQEVNITCSHN (SEQ ID NO: 8), optionally with one, two or three mutations therein,
FR2—ITWYQQFPSQGPRFIIQ (SEQ ID NO: 9), optionally with one, two or three mutations therein,
FR3—VTNEVASLFIPADRKSSTLSLPRVSLSDTAVYYC (SEQ ID NO: 10), optionally with one, two or three mutations therein,
FR4—FGTGTRLQVFP (SEQ ID NO: 11), optionally with one, two or three mutations therein,
and/or
the beta chain variable domain framework regions comprise the following sequences:
FR1—EAGVAQSPRYKIIEKRQSVAFWCNPI (SEQ ID NO: 18), optionally with one, two or three mutations therein,
FR2—LYWYQQILGQGPKLLIQ (SEQ ID NO: 19), optionally with one, two or three mutations therein,
FR3—VDDSQLPKDRFSAERLKGVDSTLKIQPAKLEDSAVYLC (SEQ ID NO: 20), optionally with one, two or three mutations therein,
FR4—FGPGTRLLVL (SEQ ID NO: 21), optionally with one, two or three mutations therein.

### Claim 15 (depends on 14)

The binding molecule of claim 14, wherein the alpha chain variable domain framework region comprises one or more of the following mutations:
L1
A
T21
P
I47
F
T56
Q
P65
S
numbered according to SEQ ID NO: 3.

### Claim 16 (depends on 15)

The binding molecule of claim 15, wherein the alpha chain variable domain framework region comprises one of the following combinations of mutations:
(a) 147F, T56Q
(b) LIA, I47F, T56Q
(c) T21P, 147F, T56Q, P65S
(d) LIA, T21P, 147F, T56Q, P65S
numbered according to SEQ ID NO: 3.

### Claim 17 (depends on 14)

The binding molecule of claim 14, wherein the beta chain variable domain framework region comprises the following mutation:
R16
G
numbered according to SEQ ID NO: 13.

### Claim at position 8

18-20. (canceled)

### Claim 21 (depends on 9)

The binding molecule of claim 9, wherein the alpha chain variable domain comprises the amino acid sequence of SEQ ID NO: 34 and the beta chain variable domain comprises the amino acid sequence of SEQ ID NO: 48.

### Claim 22 (depends on 9)

The binding molecule of claim 9, which comprises at least part of a TCR alpha chain constant domain and/or at least part of a TCR beta chain constant domain.

### Claim 23 (depends on 9)

The binding molecule of claim 9, which is an alpha-beta heterodimer, having an alpha chain TRAC constant domain sequence and a beta chain TRBC1 or TRBC2 constant domain sequence.

### Claim 24 (depends on 23)

The binding molecule of claim 23, wherein a non-native covalent disulphide bond links a residue of the constant domain of the alpha chain to a residue of the constant domain of the beta chain.

### Claim 25 (depends on 9)

The binding molecule of claim 9, which is in single chain format of the type V Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, or Vα-L-Vβ-Cβ, wherein Vα and Vβ are TCR α and β variable domains respectively, Cα and Cβ are TCR α and β constant domains respectively, and L is a linker sequence.

### Claim 26 (depends on 9)

The binding molecule of claim 9, which comprises or consists of a TCR comprising the alpha chain variable domain and the beta chain variable domain.

### Claim 27

(canceled)

### Claim 28 (depends on 9)

The binding molecule of claim 9, further comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), which associate to form an antigen binding moiety site that is capable of binding to an antigen.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

The binding molecule of claim 28, wherein the antigen is a T cell surface antigen.

### Claim 31 (depends on 28)

The binding molecule of claim 28, wherein the antigen is CD3.

### Claim 32 (depends on 28)

The binding molecule of claim 28, wherein
(a) the VH comprises CDRs having the following sequences:
CDR1 -
(SEQ ID NO: 66)
GYSFTGYT
or
(SEQ ID NO: 71)
GYSFTGYA;
CDR2 -
(SEQ ID NO: 67)
INPYKGVS;
and
CDR3 -
(SEQ ID NO: 68
ARSGYYGDSDWYFDV,
and/or
(b) the VL comprises CDRs having the following sequences:
CDR1
(SEQ ID NO: 62)
QDIRNY;
CDR2
(SEQ ID NO: 63)
YTS;
and
CDR3
(SEQ ID NO: 64)
QQGNTLPWT.

### Claim 33 (depends on 28)

The binding molecule of claim 28, wherein
the VH comprises an amino acid sequence as set forth in SEQ ID NO: 65 or 69, or an amino acid sequence that has at least 90% identity, such as at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to the amino acid sequence as set forth in SEQ ID NO: 65 or 69; and
the VL comprises an amino acid sequence as set forth in SEQ ID NO: 61, or an amino acid sequence that has at least 90% identity, such as at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, to the amino acid sequence as set forth in SEQ ID NO: 61.

### Claim 34 (depends on 28)

The binding molecule of claim 28, wherein the VH or VL is covalently linked to the C- or N-terminus of the alpha or beta chain of the TCR, optionally via a linker sequence, optionally wherein the linker sequence is selected from SEQ ID NOs: 72 and 78-89.

### Claim 35

(canceled)

### Claim 36 (depends on 9)

The binding molecule of claim 9, comprising an alpha chain amino acid sequence corresponding to SEQ ID NO: 58 and a beta chain-anti-CD3 amino acid sequence corresponding to SEQ ID NO: 77.

### Claim 37 (depends on 28)

The binding molecule of claim 28, comprising:
a first polypeptide chain which comprises the alpha chain variable domain and a first binding domain of a variable region of an antibody; and
a second polypeptide chain which comprises the beta chain variable domain and a second binding domain of a variable region of said antibody,
wherein the respective polypeptide chains associate such that the specific binding molecule is capable of simultaneously binding SLSNRLYYL (SEQ ID NO: 1) in complex with HLA-A*02 and an antigen of the antibody.

### Claim 38 (depends on 9)

The binding molecule of claim 9 associated with an Fc domain.

### Claim at position 27

39-42. (canceled)

### Claim 43 (depends on 9)

A pharmaceutical composition comprising the binding molecule of claim 9, together with one or more pharmaceutically acceptable carriers or excipients.

### Claim 44

(canceled)

### Claim 45 (depends on 9)

A method of treating cancer comprising administering the binding molecule of claim 9 or a pharmaceutical composition thereof.

### Claim at position 31

46-47. (canceled)
